Welcome to our dedicated page for Vivos news (Ticker: RDGL), a resource for investors and traders seeking the latest updates and insights on Vivos stock.
Vivos Inc. (OTCQB: RDGL) generates news centered on its development of radiotherapeutic devices and hydrogel-based technologies for oncology in both humans and animals. Company updates frequently highlight progress with its core platforms, RadioGel® for human use and IsoPet® for veterinary applications, which are designed to deliver targeted radiation directly to tumors while limiting exposure to healthy tissue.
Investors and observers following RDGL news will see detailed coverage of regulatory milestones for RadioGel, including Investigational Device Exemption (IDE) submissions to the U.S. Food and Drug Administration, FDA feedback, and the company’s use of pre-submission processes to refine its data on dosimetry, migration, and sterilization. Releases also describe international clinical activity, such as human trials conducted under U.S. regulatory standards and expansion efforts through Vivos Scientific India LLP.
Another major theme in Vivos news is the IsoPet animal therapy division. The company reports year-over-year growth in administered IsoPet therapies, case studies across dogs, cats, horses, and exotic animals, and certifications of new veterinary clinics, including equine and small animal hospitals. Updates often discuss clinical outcomes like equine ocular squamous cell carcinoma treatments without ocular damage, as well as subsidized case study programs intended to generate publishable data.
Additional RDGL coverage includes manufacturing and intellectual property developments, such as validation of an electron beam sterilization process under ISO 11137 and patent filings related to sterile thermogels and PrecisionGel agent-release characteristics. Vivos also issues news on strategic collaborations, notably with Exubrion Therapeutics, to coordinate clinic relationships and co-market IsoPet in equine oncology. For readers tracking the evolution of targeted radionuclide therapies and related medical devices, the Vivos Inc. news stream provides ongoing insight into clinical, regulatory, and operational progress.
Vivos Inc. (OTCQB: RDGL) has expanded its intellectual property protection by filing a particle patent in over ten patent offices, covering 63 countries. A provisional patent (63-299,930) was also filed, enhancing protection for hydrogel and particle components. The company plans to file additional claims internationally via the PCT process and a new utility patent for hydrogel innovations by Q3. Dr. Korenko emphasized the aim to strengthen their intellectual property to enhance shareholder value and establish a leadership position in precision radionuclide therapy.
Vivos Inc. (OTCQB: RDGL) has streamlined the IsoPet® therapy process by consolidating treatments into a single production run, effectively lowering production and shipping costs. This initiative was demonstrated at Johns Hopkins University, where two cats were treated using this new approach. Dr. Korenko emphasized the company's commitment to reducing costs while maintaining treatment quality for pets. Vivos' IsoPet® and RadioGel™ technologies use localized radiation for treating tumors in animals and humans, respectively, highlighting their innovation in the veterinary oncology space.
Vivos Inc. (OTCQB: RDGL) has successfully filed a particle patent in multiple countries, including the USA, EU, Japan, and others, enhancing its intellectual property strategy. The company is set to file a new utility patent for its hydrogel component later this year. This move underpins Vivos's plans to establish exclusive licensing agreements globally. Vivos has developed innovative brachytherapy treatments using Yttrium-90 for tumors in animals and humans, with its products aiming to offer effective radiation therapy while minimizing side effects.
Vivos Inc. (OTCQB: RDGL) provided a recap of its 2021 progress and future objectives. The company highlighted advancements in its IsoPet® animal therapy, including successful treatments and the formation of new regional clinics. For human therapy, RadioGel™ is undergoing FDA processes, with an upgraded Quality Management System in place. Challenges from the COVID-19 pandemic have been addressed, significantly improving hydrogel production efficiency. Financially, the company reports a strong capital structure with no toxic debt.
Vivos Inc. (OTCQB: RDGL) recently met with the FDA to discuss the Investigational Device Exemption for its RadioGel™ treatment for recurrent thyroid cancer. The FDA provided beneficial guidance, suggesting a Q-Submission path for expedited review and offering insights on clinical testing protocols. Vivos's representatives from Mayo Clinic effectively communicated the medical necessity for RadioGel™. CEO Mike Korenko noted that this pivotal meeting could prevent a rejected IDE submittal, emphasizing the company's readiness to cover costs for final IDE submission.
Vivos Inc. (OTCQB: RDGL) has announced a partnership with the Johns Hopkins Veterinary Clinical Trials Network for the Isopet® initiative, aimed at conducting animal studies on specific cancers. This collaboration is expected to enhance data collection for publishing in leading journals, thereby increasing awareness and acceptance of Isopet® within the veterinary oncology community. The Isopet® technology, based on yttrium-90, targets tumor treatment in animals and parallels the human treatment method, Radiogel™. The company aims to expand its regional centers and establish a robust presence in the veterinary market.
Vivos Inc. (OTCQB: RDGL) has announced that Johns Hopkins University is now an Isopet® regional clinic, which will conduct new studies on various cancers. This collaboration aims to generate high-quality data for publication, enhancing awareness within the veterinary oncology community. The Isopet® device, based on Yttrium-90, is designed to treat animal tumors effectively and can drive revenue through sales to veterinary hospitals and clinics. The FDA confirmed Isopet® as a medical device in 2018, streamlining its market introduction.
Vivos Inc. (OTCQB: RDGL) has signed a Memorandum of Understanding with the Animal Hospital Surgical Center in East Meadow, New York, to establish an IsoPet regional therapy center. This center will focus on treating cancerous tumor margins post-surgery, potentially extending pet lives. Following the acquisition of a radioactive material handling license and necessary training, the center aims to expand its capabilities to treat other solid tumors. The initiative is backed by the Veterinary Medicine Advisory Board, led by Dr. Mike Korenko.
Vivos Inc. (OTCQB: RDGL) has successfully developed nine certification training modules in collaboration with FX Masse, aimed at establishing regional clinics for IsoPet therapy. These modules, now available on the FX Masse website, facilitate a flexible learning environment for new clinics before hands-on training. The training process will be linked to handling licenses for radioactive materials. With the usage of innovative hydrogel technology, Vivos Inc. delivers targeted radiation therapy for tumors in both animals and humans, enhancing treatment safety and efficacy.
Vivos Inc. (OTCQB: RDGL) announced the submission of its Investigational Device Exemption (IDE) for the Early Feasibility Medical Device Study of Y-90 RadioGel™ to the FDA. This marks a significant milestone, encouraging enhanced communication and an efficient review process. The IDE includes the Mayo Clinic's Clinical Trial Protocol. Dr. Mike Korenko noted FDA support for the project. RadioGel™ aims to treat tumors using localized radiation, reducing side effects associated with traditional therapies. This IDE submission signals Vivos's progress in cancer treatment innovation.